Please assess the completion status of the following clinical trial:

Trial Title: MitraClip System in Australia and New Zealand

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older.~* MR ≥ 3+ .~* Transseptal catheterization and femoral vein access feasible.~* Placement of the MitraClip device on mitral leaflets feasible.~* Mitral valve orifice area ≥ 4.0 cm2.~* Written informed consent obtained.~* The patient agrees to return for follow-up visits.~Exclusion Criteria:~* Need for emergency surgery, other cardiac surgery.~* Coronary artery disease (CAD), atrial fibrillation (AF), other valve disease.~* Prior mitral valve repair surgery, mechanical prosthetic valve, or ventricular assist device (VAD).~* Active endocarditis or rheumatic heart disease; leaflets degenerated from endocarditis or rheumatic disease.~* Transesophageal echocardiography (TEE) contraindicated.~* Known hypersensitivity or contraindication to trial or procedure medications which cannot be managed medically.~* Currently participating in investigational drug trial or another device trial that has not yet completed the primary endpoint or that interferes with the MitraClip System ANZ Clinical Trial.~* Pregnant or planning pregnancy within next 12 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MitraClip Implant (Type: None): Eligible patients undergoing a MitraClip procedure in Australia and New Zealand

Based on this trial design, predict the completion outcome and termination type (if applicable).